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Abstract
Background: The glucocorticoid receptor gene (NR3C1) has been suggested as a candidate gene affecting
juvenile idiopathic arthritis (JIA) course and prognosis. The purpose of this study is to investigate the glucocorticoid
receptor gene BclI polymorphism (rs41423247) in JIA patients, the gene’s role in susceptibility to juvenile idiopathic
arthritis, and its associations with JIA activity, course and bone mineralization.
Methods: One hundred twenty-two Caucasian children with JIA and 143 healthy ethnically matched controls were
studied. We checked markers of clinical and laboratory activity: morning stiffness, Ritchie Articular Index (RAI),
swollen joint count (SJC), tender joint count (TJC), physician’s visual analog scale (VAS), hemoglobin level (Hb),
leukocyte count (L), platelet count (Pl), Westergren erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),
albumin, DAS and DAS28. Bone mineralization was measured by dual-energy X-ray absorptiometry (DXA) of lumbar
spine L1-L4. Assessments of bone metabolism included osteocalcin, C-terminal telopeptide (CTT), parathyroid
hormone (PTH), total and ionized calcium, inorganic phosphate and total alkaline phosphatase (TAP). BclI
polymorphism was genotyped by polymerase chain reaction restriction fragment length polymorphism.
Results: No association was observed between glucocorticoid receptor gene polymorphism and the presence or
absence of JIA. In girls with JIA, the presence of the G allele was associated with an unfavorable arthritis course, a
younger age of onset of arthritis (p = 0.0017), and higher inflammatory activity. The higher inflammatory activity
was demonstrated by the following: increased time of morning stiffness (p = 0.02), VAS (p = 0.014), RAI (p = 0.048),
DAS (p = 0.035), DAS28 (p = 0.05), Pl (p = 0.003), L (p = 0.046), CRP (p = 0.01). In addition, these patients had bone
metabolism disturbances as follows: decreased BA (p = 0.0001), BMC (p = 0.00007), BMD (0.005) and Z score (p =
0.002); and higher levels of osteocalcin (p = 0.03), CTT (p = 0.036), TAP activity (p = 0.01) and ionized calcium (p =
0.017). In boys with JIA, no significant differences were observed related to the polymorphic alleles or genotypes.
Conclusions: We suggest that G allele and the GG genotype of the glucocorticoid receptor gene BclI
polymorphism contribute to an unfavorable course and low bone mineral density in girls with JIA.
Background
Juvenile idiopathic arthritis (JIA) is a heterogeneous
group of chronic inflammatory diseases with different
degrees of joint involvement, functional disability and
decreased quality of life. JIA is classified into different
types, which vary in number and type of affected joints,
associated organ involvement, outcomes of joint
damage, and response to treatment [1]. Hypothalamic-
pituitary-adrenal axis disorders are associated with
human autoimmune diseases and have also been
demonstrated in experimental animal models of arthritis
[2]. Endogenous glucocorticoids have native anti-inflam-
matory, cytotoxic, and immunosuppressive effects [3].
Disturbances in glucocorticoid secretion or signal trans-
duction into cells through glucocorticoid receptor can
result in immune system alterations and excessive
inflammation with tissue damage. The balance between
pro-inflammatory molecules and endogenous or exogen-
ous anti-inflammatory molecules influences the degree
of inflammation, response tot h e r a p y ,d i s e a s ec o u r s e ,
prognosis, and outcome in inflammatory diseases.
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has been associated with immune reaction disorders
such as systemic lupus erythematosus, rheumatoid
arthritis, inflammatory bowel diseases, glucocorticoid
resistant asthma, and multiple sclerosis [2-5].
Glucocorticoids produce anti-inflammatory effects by
binding to intracellular glucocorticoid receptor-a
(GR-a). This complex is translocated to the nucleus
where it interacts with glucocorticoid-responsive ele-
ments of different genes. Thereby, glucocorticoids inhi-
bit production of proinflammatory cytokines (such as
IL-1, IL-2, IL-3, IL-6, IL-8, TNF-a)a n ds t i m u l a t ep r o -
duction of anti-inflammatory cytokines (such as IL-4,
IL-10, IL-13 and transforming growth factor-b)[ 5 ] .
There is a negative feedback loop that may lead to
secretion of proinflammatory cytokines (such as TNF-a,
IL-1, IL-6, and IL-8), thereby enhancing glucocorticoid
receptor expression in the cytoplasm [6]. Besides GR-a,
there is another isoform of this gene, GR-b which arises
by alternative splicing. GR-b is functionally inactive and
cannot bind glucocorticoids, but has a negative effect on
GR-a activity. Hyperexpression of GR-b has been noted
in some types of autoimmune diseases and may be a
cause of intrinsic glucocorticoid resistance.
The therapeutic response to glucocorticoids can
depend on the functional condition of the glucocorticoid
receptor (GR). Side effects of glucocorticoids, such as
Cushing syndrome, bone mineral loss, decreased height
velocity, ulcerogenesis, and secondary immunоdeficiency
also are associated with the functional condition of the
GR [7]. It is likely that both the desirable anti-inflamma-
tory effects and the undesirable side effects of glucocor-
ticoids are associated not only with polymorphisms of
the GR gene, but also with complicated interactions
with many other genes crucial to inflammation, immune
system function, and bone and drug metabolism. GR is
present in cells of the synovium (synoviocytes, fibro-
blasts, lymphocytes, and macrophages) of patients with
inflammatory joint disease [8], exerting local effects in
joints.
We hypothesize that that different alleles of the gluco-
corticoid receptor gene influence JIA course and prog-
nosis This hypothesis was suggested by findings that
many rheumatoid arthritis patients respond well to exo-
genous glucocorticoids, but some fail to do so [9,10].
Among the several known functionally relevant alleles
of the GR, the alleles comprising the GR BclIp o l y -
morphism (rs 41423247) may be important in JIA. First
discovered as a restriction fragment length polymorph-
ism after digestion of GR DNA with BclI, these alleles
are determined by a single nucleotide variation -
cytosine (most common) or guanine - at position 647 in
intron 2. The allele containing cytosine is referred to as
allele C, and the allele containing guanine as allele G,
resulting in three possible genotypes at this position:
homozygous CC, heterozygous GC and homozygous GG
[11]. This polymorphism has been associated with
hypertension, higher body mass index, and abdominal
obesity [12-15]. In the present study we have investi-
gated the pattern of BclI polymorphism of the GR gene
in JIA patients, and the relationships of the genotypes to
JIA course and arthritis activity.
Methods
Patients and controls
Approval was obtained from the Saint-Petersburg State
Pediatric Medical Academy committee on the ethics of
research on human beings. Blood samples were obtained
after informed written consent. All specimens for the
labs were collected at the same time as the DNA speci-
mens. One hundred and twenty two children with JIA
were enrolled in the study. Each child was a patient of
the Saint-Petersburg State Pediatric Medical Academy
rheumatology clinic. We enrolled all patients who ful-
filled the EULAR JIA criteria and agreed to take part in
our study. Age of study subjects ranged from 1.5 years
to 17 years, with a mean age of 11.3 years ± 4.36 years.
There were 43 boys (35.2%) and 79 girls (64.8%). All
patients were of Caucasian race. Only one child per
family was enrolled. The mean age of disease onset was
7.81 ± 4.66 years. The average duration of the disease at
the time of inclusion in our study was 3.57 years ± 3.49
years. All patients were divided into 3 groups according
to arthritis type: oligoarticular 68 (55.7%), polyarticular
41 (33.6%) and systemic 13 (10.7%). Extended oligoarti-
cular patients were included in polyarticular group.
Thirty patients (24.6%) were treated with corticosteroids.
DNA samples were obtained from 143 control subjects
without a personal history of autoimmune diseases
according to records of general pediatrics (DNA bank of
laboratory of molecular diagnostics of Saint-Petersburg
State Pediatric Medical Academy).
For assessment of JIA activity, clinical markers and
special indexes were used. The clinical markers
included: morning stiffness (in minutes), Ritchie Articu-
lar Index (RAI), swollen joints count (SJC), tender joints
count (TJC), and the physician’s visual analog scale
(VAS) measured in millimeters on a 100 mm line.
Other markers included: hemoglobin level (Hb), leuko-
cyte count (L), platelet count (Pl), Westergren erythro-
cyte sedimentation rate (ESR), C-reactive protein (CRP),
and albumin. DAS and DAS28 indexes were measured
in all patients.
Bone mineralization was measured by dual-energy
X-ray absorptiometry (DXA) of lumbar spine at L1-L4
(Hologic QDR 4500C densitometer with reference
pediatric database). Densitometry parameters, such as
bone area (BA, cm
2), bone mineral content (BMC,
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grams/cm
2 and in Z score, SD) were all evaluated. Low
bone mineral density for chronological age was defined
by Z score < 2 SD, according to the recommendation of
the International Society for Clinical Densitometry,
2007.
For assessment of bone metabolism the following
measures were used: osteocalcin (bone gla-protein, a
marker of osteosynthesis), C-terminal telopeptides
(CTT, products of collagen I type degradation and a
marker of bone resorption), and parathyroid hormone
(PTH) by immunochemiluminiscent assay. Also levels of
total and ionized calcium (Ca++), inorganic phosphate
and total alkaline phosphatase (TAP) were determined.
Genetic analysis
Detection of GR gene (NR3C1 - nuclear receptor sub-
family 3, group C, member 1) BclI-polymorphism (rs
41423247) was accomplished by the following previously
published method [16]: Polymerase chain reactions (20
μl final volume) contained 1 μg of genomic DNA, 250
pmol of each primer, 10мМ Tris-HCI pH 8.4, 0.5mM
MgCI2, 50mM KCl, 0.2mМ dNTPs and 1U Taq poly-
merase with the following conditions: initial denatura-
tion at 94°C for 5 min; 40 cycles of denaturation at 94°C
for 30 s, annealing at 59°C for 30 s, and extension at
72°C for 45 s; followed by a final extension at 72°C for
7 min. The primers used were (5’to 3’) for intron B BclI
SNP: forward primer 5’ AAATTGAAGCTTAA-
CAATTTTGGC 3’ and reverse primer 5’ GCAGTGAA-
CAGTGTACCAGACC 3’. The PCR product had a
length 206 bp. To detect the presence of the BclIp o l y -
morphism, this PCR product was digested by Ksp 22I
endonuclease ("Sybenzyme”, Russia - specificity identical
to BclI) followed by separation in agarose gel electro-
phoresis. Individuals with the CC genotype had 2 frag-
ments of 90 and 116 bp due to the presence of the BclI
site. Individuals with the GG genotype had an uncut
fragment of 206 bp. Those who were heterozygous (GC
genotype) had fragments of 90, 116, and 206 bp. Allele
G, also known as the 4.5 kb allele or the long allele, is a
minor allele [13].
Statistical analysis
Associations between the GR polymorphisms and JIA
markers and course were analyzed with the SPSS for
Windows, release 11. We utilized t-test, chi-square test,
and correlation analysis. Because we had a restricted
number of JIA boys with GG genotypes for statistical
analysis, all boys were divided in two groups: carriers of
the G allele (GG and GC genotypes) and carriers of CC
genotype (no G allele). P-values < 0.05 were considered
to indicate a significant difference.
Results
The distribution of BclI genotypes and alleles in JIA
patients and controls, separately in girls, boys, and total
group, is shown in Table 1. There were no differences
between results found in JIA cases and in healthy con-
trols, with no deviation from Hardy-Weinberg equili-
brium. In regression analysis the role of the G allele in
risk for JIA was not significant (p = 0.43). The frequency
of the G allele was 32.3% in oligo JIA, 41.5% in poly JIA,
and 42.3% in systemic JIA. Genotypes distribution and
sex differences in JIA subtypes shown in Table 2.
We analyzed whether differences in arthritis markers
between boys and girls depended on polymorphic geno-
types. There was a positive correlation between the pre-
sence of the G allele and inflammatory markers, such as
ESR (r = 0.21), CRP (r = 0.21), and platelet count (r =
0.19). There was a negative correlation with albumin
level (r = -0.17). In regression analysis, the presence of
the G allele had a significant influence on younger age
of onset of JIA (p = 0.02), morning stiffness (p = 0.04),
SJC (p = 0.03), RAI (p = 0.05), DAS (p = 0.02), DAS 28
(p = 0.03), platelet count (p = 0.01) and albumin level
(p = 0.05). For other parameters of JIA inflammatory
activity, such as TJC, VAS, ESR, CRP, Hb and leukocyte
count, the presence of the G allele was insignificant.
There also was no significant influence on parameters of
bone mineral density - Z-score (p = 0.15) and presence
of low bone mineral density for chronological age (p =
0.15). Girls with JIA who have the G allele had an
increase in some markers of inflammation and severity
of arthritis, and had disease onset at a younger age
(Tables 3, 4).
We did not detect significant differences in the fre-
quency of patients with different genotypes treated with
steroids. Twenty percent of children with the CC geno-
type and 27.7% of children with the G allele (CG + GG
genotypes) received steroids (p = 0.44).
In regression analysis numerous markers of JIA activ-
ity influenced the presence of low bone mineral density
for chronological age: morning stiffness (p = 0.01), SJC
(p = 0.015), TJC (p = 0.01), VAS (p = 0.004), RAI (p =
0.04), DAS (p = 0.0006), DAS 28 (p = 0.01), platelet
count (p = 0.007), CRP (p = 0.01) and albumin level (p
= 0.03). Other factors (age of onset of JIA, duration of
JIA, Hb, leukocyte count, and ESR) had no significant
influence on the presence of low BMD. Girls with JIA
who have the G allele had the combination of lower
bone mineralization parameters with higher levels of
osteocalcin, C-terminal telopeptides, ionized calcium,
and total alkaline phosphatase (Tables 5, 6). A strong
correlation between the G allele and bone mineraliza-
tion parameters was found: BMC (r = -0.39), BMD
(r = -0.31). A negative correlation with bone area
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found in carriers of the G allele. The frequency of low
bone mineral density (LBMD) for chronological age dif-
fered among JIA subtypes: 11.8% in oligo JIA, 22.0% in
poly JIA, and 54.8% in systemic JIA. Because the sys-
temic JIA patients are those with the highest levels of
inflammation and the most steroid use, the influence of
the G allele is unlikely to be clinically significant in
determining low bone mineral density.
Discussion
Since their discovery in 1949, glucocorticoids have been
commonly used for treatment of pediatric and adult
rheumatic diseases. On one hand, glucocorticoids have
strong and rapid anti-inflammatory effects; on the other
hand, long-term use is associated with a many adverse
e f f e c t sa n ds o m e t i m e sw i t he v e n t u a ll o s so ft h e r a p e u t i c
effect. Nearly 30% of adult rheumatoid arthritis patients
have been reported to become glucocorticorticoid resis-
tant (absence or failure of an expected response to treat-
ment) in 3-6 months [7]. There are several mechanisms
that may be important to resistance and susceptibility to
glucocorticoids, including reduction of the number of
glucocorticoid receptors and/or a reduced affinity for
the ligand, polymorphisms in GR genes, and differences
in other genes that modify the glucocorticoid response
(transcription factors, post-translational modifications,
and the activity of GRb [7]).
In our study we have not detected an association
between BclI genotypes and susceptibility to JIA, but we
have shown an association of the G allele and GG geno-
type with both a younger age of JIA onset and markers
of higher inflammatory activity and arthritis severity.
We did not find any significant association of the GG
genotype with subtype of JIA, but we did find an insig-
nificant imbalance of subtypes between the two sexes
(girl prevalence in polyarticular and systemic patients)
and an insignificant GG genotype prevalence in these
two JIA subtypes. These trends could be a reason that
the detected associations occur mostly in girls, but per-
haps a high prevalence of the GG genotype in polyarti-
cular and systemic patients is related to the more severe
course of these subtypes.
In previous reports, BclI polymorphic genotypes were
not associated with a risk of rheumatoid arthritis in
Caucasian patients, and there were no differences in
genotype distribution in rheumatoid arthritis patients
with and without erosions or the presence of the HLA-
DRB1 allele [17]. Similar results have been reported in
patients of Korean origin. In this study of adult RA
patients, there was no association between BclIp o l y -
morphic genotypes and patients with rheumatoid factor,
Table 1 The distribution of BclI genotypes and alleles in JIA children and controls
Girls CC CG GG p Boys CC CG GG p Total CC CG GG p
JIA 0.48 JIA 0.13 JIA 0.6
n = 79 30 34 15 n = 43 20 21 2 n = 122 50 55 17
% (38.0) (43.0) (19.0) % (46.5) (48.9) (4.6) % (41.0) (45.1) (13.9)
Controls Controls Controls
n = 70 25 36 9 n = 73 25 36 12 n = 143 50 72 21
% (35.7) (51.4) (12.9) % (34.2) (49.3) (16.5) % (35.0) (50.3) (14.7)
Alleles C G p C G p C G p
JIA 94 64 0.82 JIA 61 25 0.09 JIA 155 89 0.48
Controls 86 54 Controls 86 60 0.09 Controls 172 114
Table 2 Distribution of BclI genotypes and alleles in JIA subtypes and controls
Subtypes Oligoartricular Polyarticular Systemic Controls
Gender Boys Girls Boys Girls Boys Girls Boys Girls
47.0% 53.0% 22.0% 78.0% 15.4% 84.6% 49.0% 51.0%
Genotypes
CC 16 16 4 9 0 5 25 25
% 50.0% 44.4% 44.4% 28.1% 0.0% 45.4% 34.2% 35.7%
CG 14 14 5 17 2 3 36 36
% 43.8% 38.9% 55.6% 53.1% 100.0% 27.3% 49.3% 51.4%
G G 2606031 2 9
% 6.2% 16.7% 0.0% 18.8% 0.0% 27.3% 16.5% 12.9%
p (vs Controls) 0.19 0.47 0.41 0.63 0.37 0.26
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recent study in a Greek RA population, the role of BclI
and other polymorphisms in RA susceptibility was
investigated. Among GRa intron 2 polymorphisms
rs33388, rs33389, and BclI, and the GRb variant rs6198,
only the difference in rs33388 genotypes between
RA patients and controls was marginally significant.
However, several combined genotypes (haplotypes) of
these polymorphic genotypes were related with RA
susceptibility [9].
The association of BclI polymporphisms with other
diseases besides RA has also been investigated, with
varying results. In patients with multiple sclerosis, no
increased frequency of BclI polymorphic genotypes and
alleles was detected. There has been no evidence of per-
ipheral glucocorticoid sensitivity in multiple sclerosis
patients [19]. In childhood acute lymphoblastic leuke-
mia, researchers have reported conflicting results. In
one study no association between BclI genotypes and
glucocorticoid susceptibility in vivo and in vitro was
observed [20]. Another study showed an association
between homozygosity for allele G of the BclIp o l y -
morphism and overall survival [21]. In the study of
pediatric steroid-responsive nephrotic syndrome (SRNS)
from Poland, no associations of polymorphic genotypes
and alleles of the glucocorticoid receptor gene (BclI,
rs33389 and rs33388) with nephrotic syndrome were
observed. The distribution of individual polymorphisms
and three-marker haplotypes was similar in healthy chil-
dren and SRNS patients, but haplotype BclI G, rs33389
T, rs33388 A was associated with a higher glucocorti-
coid sensitivity [22]. In a population of Crohn Disease
patients, a significantlyh i g h e rf r e q u e n c yo ft h e
BclI polymorphism was found as compared to healthy
volunteers [23].
The relationship between BclI polymorphisms and
glucocorticoid sensitivity has been reviewed [24]. In
healthy men, the GG genotype was associated with high
cortisol levels compared with CC; healthy people with
the GG genotype had enhanced sensitivity of skin, but
low sensitivity of white blood cells, to glucocorticoids
[25]. In an elderly Dutch population, the presence of the
G allele was associated with lower cortisol levels after a
dexamethasone suppression test, suggesting an increased
Table 3 Arthritis activity markers in JIA girls with polymorphic GR genotypes
Parameter CC GC GG p1 p2 p3
Onset age, years 9.07 ± 4.9 6.9 ± 4.8 5.38 ± 3.1 0.04 0.09 0.0017
Morning stiffness, min 66.2 ± 75.0 103.4 ± 85.8 129.0 ± 98.5 0.03 0.19 0.02
SJC 5.53 ± 6.74 6.03 ± 7.2 11.8 ± 14.1 0.39 0.07 0.06
TJC 7.03 ± 8.0 7.8 ± 6.72 14.7 ± 20.3 0.37 0.11 0.09
VAS, mm 36.3 ± 20.8 39.0 ± 22.4 55.0 ± 27.5 0.02 0.03 0.014
RAI 12.37 ± 14.3 15.3 ± 19.1 23.9 ± 23.4 0.24 0.11 0.048
DAS 2.97 ± 1.7 5.3 ± 1.7 4.3 ± 2.4 0.25 0.07 0.035
DAS 28 3.44 ± 1.5 3.77 ± 1.4 4.3 ± 1.7 0.19 0.14 0.05
Hemoglobin, g/l 123.0 ± 14.5 119.8 ± 14.3 118.5 ± 15.6 0.18 0.39 0.18
Leukocytes, ×10
9/l 7.61 ± 2.26 8.78 ± 3.2 8.66 ± 2.5 0.046 0.45 0.09
Platelets, ×10
9/l 232.3 ± 60.2 283.5 ± 83.8 286.3 ± 95.3 0.003 0.46 0.03
ESR, mm/h 14.5 ± 19.3 14.3 ± 14.7 15.6 ± 15.3 0.48 0.39 0.42
CRP, mg/l 4.0 ± 9.6 19.3 ± 37.5 18.4 ± 30.8 0.01 0.46 0.048
Albumin, % 55.5 ± 6.9 51.5 ± 8.5 50.9 ± 8.5 0.02 0.41 0.04
р1 - comparison between carriers СС and GC genotypes.
р2 - comparison between carriers GC and GG genotypes.
р3 - comparison between carriers СС and GG genotypes.
Table 4 Arthritis activity markers in JIA boys with
polymorphic GR genotypes
Parameter СС GC + GG p
Onset age, years 8.37 ± 4.95 8.6 ± 4.3 0.43
Morning stiffness, min 69.3 ± 73.6 61.2 ± 78.6 0.36
SJC 2.6 ± 3.4 5.2 ± 9.3 0.11
TJC 3.25 ± 3.5 6.35 ± 11.2 0.11
VAS, mm 29.95 ± 19.0 25.65 ± 16.1 0.21
RAI 6.15 ± 6.9 8.74 ± 12.5 0.2
DAS 2.22 ± 1.07 2.55 ± 1.6 0.21
DAS 28 2.89 ± 1.2 3.25 ± 1.3 0.17
Hemoglobin, g/l 129.4 ± 18.6 125.3 ± 19.1 0.24
Leukocytes, ×10
9/l 7.7 ± 2.1 7.63 ± 3.01 0.45
Platelets, ×10
9/l 261.0 ± 110.1 262.5 ± 93.6 0.48
ESR, mm/h 13.0 ± 13.8 13.22 ± 15.7 0.48
CRP, mg/l 6.6 ± 15.2 10.2 ± 21.2 0.26
Albumin, % 52.8 ± 8.9 52.0 ± 8.9 0.25
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GG genotype was associated with more severe lung
damage (related to neutrophil infiltration of airways)
and decreased glucocorticoid sensitivity [26]. In the
Longitudinal Ageing Study Amsterdam in older men
and women, females with the GG genotype had a higher
cortisol level, and presence of the GG genotype was
associated with lower trochanteric region bone mineral
density in the total population [27]. Also, as previously
noted, this polymorphism has been described to be asso-
ciated with metabolic disturbances, such as increased
blood pressure, increased abdominal obesity, and
increased body mass index [28].
It should be emphasized that the way in which the
BclI polymorphism may alter glucocorticoid effects is
not known. As explained by Manenschijn et al., “This
polymorphism is intronic, and its location does not
involve a coding, regulatory or splicing part of the GR
gene. It is possible that this polymorphism is in linkage
with other variations, e.g., in the promoter region, or
linked to other functionally important polymorphisms”
[24].
In JIA, genetic factors can act differently in females vs
males. For example, in another study, female JIA
patients presented a higher frequency of a 14-bp inser-
tion/deletion polymorphism as compared to healthy
female children. This difference was observed in all JIA
subtypes. No such difference was observed in RA
patients [29]. In our study, the G allele and the GG gen-
otype of the BclI polymorphism was associated with
more active JIA only in girls.
Conclusions
The present study has addressed the role of BclIG R
gene polymorphism in JIA course, bone mineralization,
and prognosis. In girls with JIA, the presence of the G
allele was associated with an unfavorable arthritis
course, a younger age of onset of arthritis, and some
markers of higher inflammatory activity. We conclude
that GR polymorphism could be a risk factor for more
severe disease course or lower susceptibility to endogen-
ous and exogenous glucocorticoids. Further investigation
is required to test this hypothesis, which may provide
new insights into JIA pathogenesis and the patient
response to glucocorticoid treatment.
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Table 5 Markers of bone mineralization and metabolism in JIA girls with polymorphic GR genotypes
Parameter CC GC GG p1 p2 p3
ВА, см
2 51.9 ± 11.0 38.0 ± 12.6 32.3 ± 13.5 0.00005 0.11 0.0001
BMC, grams 43.5 ± 13.8 28.1 ± 16.8 19.6 ± 15.2 0.0004 0.07 0.00007
BMD, gms/см
2 0.816 ± 0.15 0.677 ± 0.22 0.566 ± 0.19 0.005 0.06 0.048
BMD - Zscore (SD) 0.03 ± 0.85 0.007 ± 0.9 -0.931 ± 0.88 0.46 0.003 0.002
Osteocalcin, ng/ml 82.5 ± 5.1 87.3 ± 44.8 114.3 ± 39.8 0.37 0.05 0.03
CTТ, ng/ml 0.95 ± 0.34 1.02 ± 0.37 1.24 ± 0.42 0.28 0.09 0.036
PTH, pmol/ml 2.29 ± 1.23 1.9 ± 0.83 2.08 ± 0.64 0.11 0.25 0.26
Ca, mmol/l 2.4 ± 0.15 2.36 ± 0.14 2.38 ± 0.13 0.09 0.29 0.29
Ca
++, mmol/l 1.02 ± 0.12 1.05 ± 0.11 1.1 ± 0.11 0.18 0.07 0.017
P inorganic, mmol/l 1.54 ± 0.2 1.61 ± 0.2 1.55 ± 0.2 0.1 0.23 0.44
TAP, U/l 293.5 ± 119.8 360.8 ± 116.1 328.8 ± 115.8 0.01 0.19 0.17
р1 - comparison between carriers СС and GC genotypes.
р2 - comparison between carriers GC and GG genotypes.
р3 - comparison between carriers СС and GG genotypes.
Table 6 Markers of bone mineralization and metabolism
in JIA boys with polymorphic GR genotypes
Parameter CC GC + GG p
BA, CM
2 45.12 ± 16.1 45.26 ± 8.9 0.49
BMC, grams 32.79 ± 19.2 29.72 ± 13.1 0.32
BMD, gms/CM
2 0.661 ± 0.21 0.642 ± 0.16 0.39
BMD - Zscore (SD) -0.15 ± 1.06 -0.349 ± 1.33 0.34
Osteocalcin, ng/ml 130.5 ± 50.1 150.7 ± 54.5 0.21
CTT, ng/ml 1.46 ± 0.48 1.54 ± 0.45 0.36
PTH, pmol/ml 2.03 ± 0.9 2.75 ± 1.85 0.23
Ca, mmol/l 2.35 ± 0.16 2.38 ± 0.13 0.15
Ca
++, mmol/l 1.12 ± 0.11 1.08 ± 0.09 0.11
P inorganic, mmol/l 1.6 ± 0.21 1.59 ± 0.16 0.43
TAP, U/l 376.0 ± 106.2 384.5 ± 127.3 0.41
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